BLOG

Oral AMD treatment meets phase 2 endpoints

At the American Society of Retina Specialists meeting, Michael Stewart, MD, chairman and professor of ophthalmology at the Mayo Clinic of Jacksonville, Florida, discusses phase 2 results of AKST4290 (Alkahest), an orally administered small molecule CCR3 inhibitor.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}